Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor tyrosine kinase inhibitors. Final results and analysis of prognostic factors are reported.METHODS: Patients with mRCC (N=416) were randomized (2:1) to everolimus 10 mg/d (n=277) or placebo (n=139) plus best supportive care. Progression-free survival (PFS) and safety were assessed to the end of double-blind treatment. Mature overall survival (OS) data were analyzed, and prognostic factors for survival were investigated by multivariate analyses. A rank-preserving structural failure time model estimated the effect on OS, correcting for crossover from placebo to everolimus.RESULTS: The median PFS was 4.9 months (everolimus) versus 1.9 months (placebo) (hazard ratio [HR], 0.33; P <0.001) by independent central review and 5.5 months (everolimus) versus 1.9 months (placebo) (HR, 0.32; P <0.001) by investigators. Serious adverse events with everolimus, independent of causality, in ≥5% of patients included infections (all types, 10%), dyspnea (7%), and fatigue (5%). The median OS was 14.8 months (everolimus) versus 14.4 months (placebo) (HR 0.87; P=0.162), with 80% of patients in the placebo arm crossed over to everolimus. By the rank-preserving structural failure time model, the survival corrected for crossover was 1.9-fold longer (95% confidence interval, 0.5–8.5) with everolimus compared with placebo only. Independent prognostic factors for shorter OS in the study included low performance status, high corrected calcium, low hemoglobin, and prior sunitinib (P <0.01).CONCLUSIONS: These results established the efficacy and safety of everolimus in patients with mRCC after progression on sunitinib and/or sorafenib.
Authors and Affiliations
Robert J. Motzer
Keywords
Related Articles
- EP ID EP53095
- DOI -
- Views 265
- Downloads 0
Pericardial effusion endangering cardiac tamponade in cases of patients suffering for malignant diseases – diagnostics and management
Pericardial effusion endangering cardiac tamponade is a condition of high risk of life loss. In case of endangering cardiac tamponade the most important are: fast diagnosis, pericardiocentesis and drainage of the pericar...
Quality of life in oncology and quality of life in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Fu...
Dermatofibrosarcoma protuberans (DFSP) – advances in diagnostics and therapy
Dermatofibrosarcoma protuberans is a rare soft tissue sarcoma with a superficial growth. It has an estimated incidence of 4 cases per one million persons per year. DFSP is preferentially located on the trunk. It can appe...
Pazopanib - dilemmas in kidney cancer treatment
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in in...
Patient with metastatic renal cell carcinoma treated successfully with pazopanib for four years.
We present a case of a patient with metastatic renal cell carcinoma who was treated with pazopanib in the first-line treatment. Although nephrectomy was not performed, there was a positive reaction to the therapy with mu...